Umang Vohra of Cipla reasoned that almost 80 percent of the drugs sold by Cipla in the US market are manufactured in the US itself. He said it will not be a challenge to manufacture all its supplies in the US itself if asked to do so by authorities.
first published: Mar 2, 2017 01:33 pm
A collection of the most-viewed Moneycontrol videos.
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
